Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Ventyx Biosciences (NASDAQ:VTYX) announced Tuesday that a small mid-stage trial for VTX3232, its experimental therapy for Parkinson’s disease, reached the primary endpoint related to safety and ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Members of the Ventyx management team will also host investor meetings during the conferences. Webcasts of the presentations will be available in the Investors and News section of the Ventyx ...

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid ...

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company ...

Ventyx Biosciences, Inc. thinks that with its higher exposure, VTX958 may approach biologics in their response rates, but there is no such data available to validate that claim as of now.

Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials ...